Crizotinib: from discovery to accelerated development to front-line treatment

Ann Oncol 2016; 27: iii35–iii41 (doi: 10.1093/annonc/mdw304)

An error has been corrected on p. iii40, where trials were numbered incorrectly. The corrected sentence reads:

In a joint analysis of 194 patients with RECIST-defined disease progression in the PROFILE 1001 and PROFILE 1005 studies, 120 continued to receive crizotinib [36].